Quell Therapeutics Ltd, a world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, and eXmoor pharma, the full-service cell and gene therapy manufacturing partner, announce a strategic partnership for the manufacture of multiple autologous engineered CAR-Treg cell therapies in Quell’s pipeline targeting autoimmune diseases. Source: eXmoor Pharma press release 24/9/24